Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis

Domenica Lorusso, Ilaria Sabatucci, Giuseppa Maltese, Stefano Lepori, Elisa Tripodi, Giorgio Bogani, Francesco Raspagliesi

Research output: Contribution to journalReview articlepeer-review


The vast majority of ovarian cancer relapses on front-line therapy and the optimal treatment of recurrent ovarian cancer remains controversial. This review is based on the relevant published literature indexed in PubMed on pegylated liposomal doxorubicin (PLD), either alone or in combination with other drugs, as one option in relapsed disease. PLD showed an improved pharmacokinetic profile, with a slower plasma clearance and a longer circulation time, compared to other conventional doxorubicin formulations. PLD is considered to have little potential for cardiotoxicity, even at prolonged and high cumulative doses, although there appears to be room for improvement in terms of maximal dose allowed. Notwithstanding, there remain some concerns about cardiac safety, and patient monitoring is generally advocated. No data are available on the possibility to rechallenge PLD treatment in recurrent ovarian cancer, as already known for other drugs. Optimization of treatment regimens with PLD will allow a more rational treatment in advanced ovarian cancers for which few therapeutic options are available.

Original languageEnglish
Pages (from-to)282-287
Number of pages6
Issue number4
Publication statusPublished - Aug 1 2019


  • Anthracycline
  • cardioprotection
  • ovarian cancer
  • pegylated liposomal doxorubicin
  • personalized therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis'. Together they form a unique fingerprint.

Cite this